Literature DB >> 7906604

Spinal dynorphin immunoreactivity increases bilaterally in a neuropathic pain model.

R Wagner1, J A DeLeo, D W Coombs, S Willenbring, C Fromm.   

Abstract

Increased spinal levels of dynorphin, an endogenous opioid kappa agonist, are seen in models of both chronic and acute hyperalgesia. This study determined the extent and localization of spinal immunoreactive dynorphin following sciatic cryoneurolysis (SCN), a neuropathic pain model produced by a peripheral nerve freeze lesion. SCN results in behaviors associated with neuropathic pain such as autotomy (the gnawing and scratching of the affected limb), touch-evoked and mechanical allodynia, and spontaneous nociceptive behavior. Following SCN, 4 rats that displayed autotomy and 3 rats that did not were randomly chosen for immunohistochemical staining of dynorphin-like immunoreactivity (DLIR). The area of DLIR above a standardized threshold level was quantified in both dorsal horns of each spinal cord section using a computer-assisted image analyzer to express DLIR in pixels. DLIR was observed both ipsilateral and contralateral to the injured peripheral nerve. In addition, the area of DLIR was significantly greater (P = 0.05) in rats that showed autotomy behavior (mean = 52.6 x 10(3) +/- 25.6) compared to rats with no autotomy (mean = 13.8 x 10(3) +/- 4.78). In sharp contrast to the ipsilateral dynorphin increases observed in other neuropathic pain models, we observe a bilateral increase at 21 days following SCN.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7906604     DOI: 10.1016/0006-8993(93)91339-t

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain.

Authors:  M J Schwei; P Honore; S D Rogers; J L Salak-Johnson; M P Finke; M L Ramnaraine; D R Clohisy; P W Mantyh
Journal:  J Neurosci       Date:  1999-12-15       Impact factor: 6.167

Review 2.  Pronociceptive actions of dynorphin via bradykinin receptors.

Authors:  Josephine Lai; Miaw-chyi Luo; Qingmin Chen; Frank Porreca
Journal:  Neurosci Lett       Date:  2008-04-08       Impact factor: 3.046

3.  Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance.

Authors:  Mei Xu; Michael Petraschka; Jay P McLaughlin; Ruth E Westenbroek; Marc G Caron; Robert J Lefkowitz; Traci A Czyzyk; John E Pintar; Gregory W Terman; Charles Chavkin
Journal:  J Neurosci       Date:  2004-05-12       Impact factor: 6.167

Review 4.  The Emerging Role of Spinal Dynorphin in Chronic Pain: A Therapeutic Perspective.

Authors:  Sonia Podvin; Tony Yaksh; Vivian Hook
Journal:  Annu Rev Pharmacol Toxicol       Date:  2016       Impact factor: 13.820

5.  Intrathecal delivery of farnesyl thiosalicylic acid and GW 5074 attenuates hyperalgesia and allodynia in chronic constriction injury-induced neuropathic pain in rats.

Authors:  Amteshwar Singh Jaggi; Nirmal Singh
Journal:  Neurol Sci       Date:  2012-03-02       Impact factor: 3.830

Review 6.  Does the kappa opioid receptor system contribute to pain aversion?

Authors:  Catherine M Cahill; Anna M W Taylor; Christopher Cook; Edmund Ong; Jose A Morón; Christopher J Evans
Journal:  Front Pharmacol       Date:  2014-11-17       Impact factor: 5.810

Review 7.  Modulation of the Negative Affective Dimension of Pain: Focus on Selected Neuropeptidergic System Contributions.

Authors:  Francesca Felicia Caputi; Laura Rullo; Serena Stamatakos; Sanzio Candeletti; Patrizia Romualdi
Journal:  Int J Mol Sci       Date:  2019-08-17       Impact factor: 5.923

8.  Endogenous kappa-opioid receptor systems inhibit hyperalgesia associated with localized peripheral inflammation.

Authors:  R J Schepers; Janet Lynn Mahoney; Brenda Jean Gehrke; Toni Shaun Shippenberg
Journal:  Pain       Date:  2008-03-19       Impact factor: 7.926

9.  Pain without nociceptors? Nav1.7-independent pain mechanisms.

Authors:  Michael S Minett; Sarah Falk; Sonia Santana-Varela; Yury D Bogdanov; Mohammed A Nassar; Anne-Marie Heegaard; John N Wood
Journal:  Cell Rep       Date:  2014-01-16       Impact factor: 9.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.